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Abstract
Clonal evolution of chronic lymphocytic leukemia (CLL) often follows chemotherapy and is associated with adverse
outcome, but also occurs in untreated patients, in which case its predictive role is debated. We investigated
whether the selection and expansion of CLL clone(s) precede an aggressive disease shift. We found that clonal
evolution occurs in all CLL patients, irrespective of the clinical outcome, but is faster during disease progression. In
particular, changes in the frequency of nucleotide variants (NVs) in specific CLL-related genes may represent an
indicator of poor clinical outcome.
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To the Editor
In chronic lymphocytic leukemia (CLL), the clonal
expansion acquired relevance with the NGS era, which
allowed its use for clinical monitoring. Research was
mainly performed on large CLL cohorts sampled be-
fore and after therapy [1] and only a few studies inves-
tigated clonal evolution longitudinally in stable versus
progressive untreated patients [2–4]. The key results
indicate expansion of specific clones upon therapy and
heterogeneity of mutated genes among patients, but
the extent to which the genetic dynamics differs be-
tween stable and progressive untreated CLLs is still
controversial.
To address this point, we used a CLL cohort includ-
ing untreated sequential samples from patients with
either progressive (P-CLL) or stable (S-CLL) disease.
Patients’ features are in Additional file 1: Table S1. At
each time point, the diagnosis of stable or progressive
CLL was established by the clinicians according to the cri-
teria defined during the International Workshop on
Chronic Lymphocytic Leukemia [5]. Using genome-wide
copy number variation (CNV) analysis, we investigated
copy number fluctuations in 11 stable CLLs (S-CLLs) and
15 progressive CLLs (P-CLLs). Data were processed using
the Rawcopy package [6], and paired segments were de-
fined for each patient (Additional file 2: Figure S1). Since
the percentage of CLL cells (f) in PBMCs was not always
known, analyses were performed varying f from 1 to 100%.
To define aberrant loci, we used two sets of thresholds on
log ratio (LogR) value, depending on f and on copy num-
ber (k) in CLL cells (Additional file 2: Figure S2). We did
not find significant differences in percentages of aberrant
loci between S-CLLs and P-CLLs (Fig. 1a), but the rate of
change (or slope), reflecting the rate of aberrant clones
evolving over time, was significantly higher in P-CLLs
(p ≤ 0.05, Mann-Whitney U test) (Fig. 1b). Thus, S-CLLs
and P-CLLs seemed to have the same probability of ac-
quiring or losing clones, but this phenomenon was faster
in P-CLLs. The results were validated on 6 S-CLLs and 5
P-CLLs with known percentage of CLL cells in PBMCs
(Additional file 2: Figure S3-S4), suggesting that tracking
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copy number changes does not mandatorily require know-
ledge of cancer cell percentage.
To identify genetic events associated with faster
clonal expansion, we characterized the CLL-specific
genetic features of our cohort. Analyses by qPCR of
three chromosomal abnormalities of prognostic value,
del (11q), tri (12), and del (17p) [7], did not reveal sig-
nificant differences between S-CLLs and P-CLLs
(Additional file 2: Figure S5). Subsequently, we charac-
terized 11 S-CLLs and 17 P-CLLs for point mutations
or indels in regions of 27 genes reported as mutated in
CLL (Additional file 3: Table S2). We did not register
any significant difference between S-CLLs and P-CLLs
with regard to frequency and number of nucleotide var-
iants (NVs) (data not shown). Next, we focused only on
NVs with variant allele frequencies (VAF) changing
more than 20% between longitudinal samples (dynamic
NV: dNVs, synonymous or non-synonymous). We de-
tected on average 1.18 and 3.35 dNVs per sample in S-
CLLs and P-CLLs, respectively (Additional file 4: Table
S3). P-CLLs showed higher gains/increases of dNVs
(p = 0.0008, Fisher’s test) (Fig. 2a). Patients with dNV >
Fig. 1 Longitudinal analysis of copy number aberrations in stable and progressive CLL patients. Genome-Wide Human SNP Arrays 6.0 (Affymetrix)
was used to genotype patient DNAs at the two sequential sampling points, first time point (FTP), and last time point (LTP). Data were processed
using the Rawcopy package, and paired segments (PSs) were identified between FTP and LTP of each patient (see Methods in Additional file 2).
Aberrant loci were identified by varying the percentage of cancer cells (f) using two sets of threshold on log ratio (LogR), one for DNA
amplification (LogRA) and one for DNA deletion (LogRD). a The percentage of PSs and b their slopes (ΔLogRLTP, FTP/ΔtLTP, FTP) are shown as mean
(solid line) and standard deviation (shades) based on no change, acquisition, or loss of aberration as a function of f. No change of aberration: the
considered locus was aberrant both in FTP and in LTP; acquisition of aberrations: the considered locus was aberrant only in LTP; loss of
aberrations: the considered locus was aberrant only in FTP. Red colors indicate the P-CLLs; blue the S-CLLs. p values’ graphs (lower panel) report
the Mann-Whitney U test for each f, significance was defined as p < 0.050
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1 had shorter treatment-free survival (TFS), considering
as starting point the date at first sampling (p = 0.0029)
or at diagnosis (p = 0.0004, log rank test) (Fig. 2b and
Additional file 2: Figure S6). A dNV > 1 was also
associated with poor prognostic factors, including
unmutated IGVH and trisomy 12 (p = 0.0461 and p =
0.0407, respectively, Fisher’s test) (Additional file 5:
Table S4). Patients with unmutated IGVH showed
Fig. 2 Mutational status of CLL samples. a Next-generation sequencing of 27 CLL-associated genes in 11 and 17 patients with stable and
progressive disease, respectively. Sequence variants were identified using Torrent Suite 3.4 and Variant Caller plugin 3.4.4. NVs with a coverage <
100 were not considered; NVs with a mutation frequency < 5% were not considered; NVs residing in homopolymer DNA sequences (≥ 4
nucleotides) were also not considered. Each square report either gain or loss of mutation or change in mutation frequency (> 20%) between FTP
(left side) and LTP (right side); the mutation frequency of dynamic nucleotide variants (dNVs) was reported in Additional file 4: Table S3. Fisher’s
exact tests were used to compare groups. Statistical tests were two-sided, and significance was defined as p < 0.050. b Kaplan-Meier curve of
treatment-free survival in CLL patients dichotomized based on the number of NVs that change more than 20% between FTP and LTP (dNVs)
(upper panel) and on the mutational status of the poor prognostic factor IGVH (lower panel). The median of dNVs changed across all the samples
was used as cut-off. Time to treatment was calculated from the first sampling; the last follow-up was considered for patients, which did not
undergo treatment. The Log-rank test was used to test for significance. c Mutation frequency of dNVs in stable and progressive CLL groups, and
in mutated or unmutated IGVH CLL groups; data are reported as median and interquartile range (box); whiskers range from min to max. Mann-
Whitney test was used to compare groups; **denotes a p value ≤ 0.01
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shorter TFS, supporting the reliability of our cohort
(Fig. 2b). Finally, we found that in P-CLLs the average
of dNV frequencies was higher in the first sample (p =
0.0074, Mann-Whitney U test), where it was not associ-
ated with IGVH mutational status (Fig. 2c). These find-
ings suggest that dNVs could have an exploitable
clinical relevance. However, since dNVs include synonym-
ous/non-synonymous mutations and NVs in non-coding
regions, we cannot speculate on the molecular role of the
targeted genes most frequently mutated, such as ITPKB
and NOTCH1 (Fig. 2a). Indeed, these dNVs were only used
here to track genetic evolution.
In conclusion, differently from previous studies, we
calculated VAFs on PBMCs, demonstrating that this
is reliable to track CLL evolution. In fact, an increase
of a single VAF over time indicates expansion of the
clone carrying that NV, regardless of variation in can-
cer cell fraction. Overall, our study points to a higher
genetic dynamics in P-CLLs and suggests that moni-
toring VAFs of a specific gene panel in PBMCs from
sequential samples of a CLL patient may predict dis-
ease progression.
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